Green leaf pharmaceutical Latin American market reached two cooperation to accelerate the construction of Srecon's global business system. Agency for the United States.

Greenlee Pharmaceutical Group recently entered into two new cooperation agreements in the Latin American market, working with partners to deepen the local operations of the central neuropharmaceuticals Srecon ® (Fumarate sulfate, rapid release) and Srecon slow release tablets ® (slow release preparations).
partners are CAP ALTER PHARMA, ALTER-Pharma and Laboratorios Bago.
Under the agreement, Greenleaf Pharmaceuticals granted Alter-Pharma exclusive promotion rights to the Srecon range of products in nine countries and territories, including Costa Rica, Jamaica, Trinidad and Tobago, and Greenleaf Pharmaceuticals and Laboratorios Bago deepened Srecon's business cooperation in the Argentine market, including local packaging of the product and further local production.
and its ® tablets are atypical antipsychotic drugs with antidepressant properties, and Srecon ® is mainly used to treat schizophrenia and bipolar disorder.
addition, Srecon's slow-release tablets ® approved in some areas for the treatment of depression and widespread anxiety.
As one of Greenlee Pharmaceuticals' core products in the central nervous system, Srecon's global business system has made several important advances: the company has set up a central nervous system team in China, set up its own sales force in Singapore and the Middle East, and has reached distribution and promotional strategic cooperation with local partners in many countries and regions in Asia Pacific, the Americas and Africa.
.